RxDoctor Payments Data

Jason Owyang, NP

Family · San Pablo, CANPI 1972928059

Payments from drug & device makers

$1,486in general payments, 2019–2025

Across 68 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$220
  • Lilly USA, LLC$198
  • Bayer$192
  • Edwards Lifesciences$109
  • Boehringer Ingelheim$102
  • Novartis$99
  • plus $565 from 14 others

What the payments were for

  • Food & beverage$1,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,486 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$68,434
Medicare patients
169
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$58,508
RybelsusSemaglutide24$36,812
JanuviaSitagliptin Phosphate16$21,651
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$20,927
EliquisApixaban12$16,902
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,607
Atorvastatin Calcium260$2,345
Albuterol Sulfate HfaAlbuterol Sulfate47$2,118
Ketoconazole51$1,478
Gabapentin104$1,453
Levothyroxine Sodium119$1,350
Metoprolol Succinate69$1,176
Rosuvastatin Calcium61$1,157
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$1,085
Losartan Potassium97$1,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$102$58,50834 claims
Novo NordiskRybelsus$91$36,81224 claims
MerckJanuvia$38$21,65116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in San Pablo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →